NOAEL Studies Cosmetic Ingredient

ZINGIBER OFFICINALE ROOT OIL NOAEL Studies

CAS: 8007-08-7

Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.

Back to parent ingredient page
COSMOS_DB 1 endpoint
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
COSMOS_DB NOAEL 0.4 mg/kg bw/day mouse oral 14 day Special Toxicology Study US FDA CFSAN PAFA; US FDA CFSAN PAFA Study
EFSA_OpenFoodTox_OpenFoodToxTX22809_2023.xlsx 2 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
EFSA_OpenFoodTox_OpenFoodToxTX22809_2023.xlsx NOAEL =500 mg/kg bw/day Rat oral: gavage 90 days subchronic ENDPOINTSTUDY_ID 701536; TOX_ID 13167 - OP_ID 3638 - EFSA - 2020 - Safety and efficacy of essential oil, oleoresin and tincture from Zingiber officinale Roscoe when used as sensory additives in feed for all animal species - doi:10.2903/j.efsa.2020.6147
EFSA_OpenFoodTox_OpenFoodToxTX22809_2023.xlsx NOAEL =500 mg/kg bw/day Rat oral: gavage 90 days subchronic ENDPOINTSTUDY_ID 701536; TOX_ID 13167 - OP_ID 3638 - EFSA - 2020 - Safety and efficacy of essential oil, oleoresin and tincture from Zingiber officinale Roscoe when used as sensory additives in feed for all animal species - doi:10.2903/j.efsa.2020.6147
NTP_ICE_skin_sensitization 2 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
NTP_ICE_skin_sensitization Incidence of positive responses 0 % Human Dermal - In Vivo; HPPT2020WIP; Human Maximization Test sheet=Data_invivo; excel_row=11832; Record_ID=skin_sensitization_invivo_2573; Data_Type=In Vivo; Internal_Data_Source=HPPT2020WIP; Formulation_ID=MIX906; Formulation_Name=Ginger oil; Concentration=4.0; Concentration_Units=%; Mixture=Mixture; DTXSID=DTXSID80904698; Assay=Human Maximization Test; Endpoint=Incidence of positive responses; Response=0; Response_Unit=%; Species=Human; Route=Dermal; Reference=Kligman 1972: report to RIFM|Opdyke 1974; Not available; 10.1016/0015-6264(74)90190-4; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID80904698
NTP_ICE_skin_sensitization Relative reliability score 3 unitless Human Dermal - In Vivo; HPPT2020WIP; Human Maximization Test sheet=Data_invivo; excel_row=11836; Record_ID=skin_sensitization_invivo_2573; Data_Type=In Vivo; Internal_Data_Source=HPPT2020WIP; Formulation_ID=MIX906; Formulation_Name=Ginger oil; Concentration=4.0; Concentration_Units=%; Mixture=Mixture; DTXSID=DTXSID80904698; Assay=Human Maximization Test; Endpoint=Relative reliability score; Response=3; Response_Unit=Unitless; Species=Human; Route=Dermal; Reference=Kligman 1972: report to RIFM|Opdyke 1974; Not available; 10.1016/0015-6264(74)90190-4; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID80904698
openFDA substances 4 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
openFDA substances FDA UNII substance identifier SAS9Z1SVUK UNII - - - structurallyDiverse {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"structurallyDiverse","unii_code":"SAS9Z1SVUK"}
openFDA substances FDA UNII substance identifier SAS9Z1SVUK UNII - - - structurallyDiverse {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"structurallyDiverse","unii_code":"SAS9Z1SVUK"}
openFDA substances FDA UNII substance identifier SAS9Z1SVUK UNII - - - structurallyDiverse {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"structurallyDiverse","unii_code":"SAS9Z1SVUK"}
openFDA substances FDA UNII substance identifier SAS9Z1SVUK UNII - - - structurallyDiverse {"approval_status":null,"molecular_formula":null,"source_table":"substance_identifiers_fda","substance_class":"structurallyDiverse","unii_code":"SAS9Z1SVUK"}